Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
News and Events
by Steve Usdin
FDA guidance released on June 12 broadens a safe harbor that allows medical product manufacturers to communicate with payers, PBMs, formulary committees and similar entities. A primary goal is to make it easier to base payments on outcomes not mentioned on product labels, but there could be broader effects in the loosened restrictions oncommunications between medical product developers and payers.
June 15, 2018
Jane Barlow, MD
Real Endpoints LLC
We’ve seen an explosion of value-based deals: from 10 in 2015-2016 to 25 from 2017 to Q1 2018 (and we’re on pace for 30+ this year), according to the Real Endpoints database. But we’ve also had the time to see which deals from 2015-16 haven’t worked — and why. We will take a candid look at what’s worked and what hasn’t worked in value-based agreements -- as well as preview the drugs coming to market in 2018 that could benefit from value-based agreements.
May 17, 2018
by Steve Usdin
A law that comes into effect next year will squeeze profits from moderately priced drugs that treat common, chronic conditions and increase economic incentives to develop high priced medicines for rare or acute life-threatening diseases. Manufacturers of drugs to treat common, chronic conditions will be especially hard hit.
April 9, 2018
Recent Insightsview archive >
July 2, 2018
Confirmation bias: when innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. Industry and its investors need a clear, objective lens through which they can burn away confirmation bias and see the likely access barriers their drugs will face once approvedRead full insight article >
June 18, 2018
For all of the millions who suffer from depression, the biological underpinnings of clinical depression are still not fully understood. With several high profile approval decisions and possible launches on the horizon, the stage is thus set for an emerging commercial case characterized by a new wave of effective anti-depressants, an increasingly influential assortment of payers and practitioners with generic but often ineffectual pharmacotherapy options at their disposal, and of course patients with an unabating level of need and strikingly high placebo response-rates. How will it play out?read full insight presentation >
National Business Director
Top 5 Pharma
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
President , GlaxoSmithKline U.S.